腋窝淋巴结超声造影预测乳腺癌新辅助化疗的疗效

目的探讨腋窝淋巴结超声造影对浸润型乳腺癌新辅助化疗(NAC)疗效的预测价值.方法对58例Ⅱ、Ⅲ期浸润型乳腺癌患者的腋窝转移性淋巴结于NAC前、后进行超声造影检查,观察造影增强方式并进行时间强度分析,然后与手术病理对照.结果临床评价35例有效,23例化疗无变化.NAC有效组和无变化组两组之间灌注模式差异无统计学意义.到达淋巴结皮质时间化疗前两组间比较差异无统计学意义,化疗后有效组大于化疗无变化组.化疗前的弥散时间两组间差异有统计学意义,化疗后有效组弥散时间降低.以化疗后弥散时间275秒为最佳临界点,预测的敏感性为77%,特异性为90%.达峰时间、峰值强度两组之间差异无统计学意义.结论淋巴结超声造影增强方式对预测新辅助化疗的疗效无明显特异性,但到达淋巴结皮质时间、弥散时间对预测新辅助化疗的有效性有临床价值.     

腋窝淋巴结超声造影预测乳腺癌新辅助化疗的疗效

Objective To explore the predictive value of response to neoadjuvant chemotherapy(NAC)in local advanced breast cancer with contrast-enhanced ultrasound(CEUS)of axillary lymph node.Methods CEUS of metastatic axillary lymph nodes in 58 patients stacng Ⅱ-Ⅲ breast cancer was performed before and after NAC treatment. The enhancement patterns and parameters of time-intensity curve were assessed and compared with the pathology.Results The clinic response evaluation were drug-effective in 35 cases and no change in 23 ones.There Were no significant differences in enhancement patterns between no-change and drugeffective groups.Lymph node cortex arriving time was longer in drug-effective cases than that in no-change ones after NAC,whereas it showed no significant differences before NAC.Statistical significant difierence in enhancement duration(ED)was found between the two groups before NAC,which decreased markedly in drug-effective case8 after NAC.Histopatholngic response could be predicted with a sensitivity of 77% and a specificity of 90% by standardized ED below 275 seconds after NAC.No significant difference was found in time to peak(TP),peak intensity(PI)between the two groups.Conclusion The perfusion pattern of axillary lymph node CEUS after NAC Was insufficient to predict curative effect.But the lymph node cortex arriving time and enhancement duration may be of value in the prediction of clinical response to chemotherapy.     

腋窝淋巴结超声造影预测乳腺癌新辅助化疗的疗效

Objective To explore the predictive value of response to neoadjuvant chemotherapy(NAC)in local advanced breast cancer with contrast-enhanced ultrasound(CEUS)of axillary lymph node.Methods CEUS of metastatic axillary lymph nodes in 58 patients stacng Ⅱ-Ⅲ breast cancer was performed before and after NAC treatment. The enhancement patterns and parameters of time-intensity curve were assessed and compared with the pathology.Results The clinic response evaluation were drug-effective in 35 cases and no change in 23 ones.There Were no significant differences in enhancement patterns between no-change and drugeffective groups.Lymph node cortex arriving time was longer in drug-effective cases than that in no-change ones after NAC,whereas it showed no significant differences before NAC.Statistical significant difierence in enhancement duration(ED)was found between the two groups before NAC,which decreased markedly in drug-effective case8 after NAC.Histopatholngic response could be predicted with a sensitivity of 77% and a specificity of 90% by standardized ED below 275 seconds after NAC.No significant difference was found in time to peak(TP),peak intensity(PI)between the two groups.Conclusion The perfusion pattern of axillary lymph node CEUS after NAC Was insufficient to predict curative effect.But the lymph node cortex arriving time and enhancement duration may be of value in the prediction of clinical response to chemotherapy.     

活性碳吸附丝裂霉素局部给药治疗腋淋巴结阳性乳腺癌模型的疗效研究

目的：研究丝裂霉素-活性碳混悬液(MMC—CH)局部注射给药对腋淋巴结阳性的兔乳腺癌模型的治疗效果。方法：30只雌性新西兰兔随机分为三组，每组10只、VX2肿瘤组织块悬液注射法建立乳腺癌模型，腋淋巴结最大径达到5mm时开始治疗。A组：肿瘤周围皮下注射MMC-CH；B组：肿瘤周围皮下注射丝裂霉素水溶剂(MMC-S01)；C组：注射生理盐水。A、B组单次药物剂量0．2mg／kg，每48h重复给药1次，3次治疗后切除淋巴结。比较治疗前后淋巴结体积变化，病理切片观察转移灶癌组织坏死，dTUP末端标记技术(TUNEL)检测癌细胞凋亡指数(AI)，组问差异比较采用ANOVA-Dunnett检验。结果：与MMC-Sol相比，局部注射MMC-CH对腋淋巴结癌转移灶表现出更为显著的疗效。治疗后A、B、C组淋巴结平均生长率分别为2．645、3．175和3．518，A组显著低于B、C组(P值分别为0．012和0．000)。A、B、C组平均AI值分别为15．94％、5．18％和4．60％，A组显著高于B组(P=0．000)，B组又显著高于C组(P=0．020)。病理检查发现，A组淋巴结转移癌细胞大量坏死。结论：局部注射MMC-CH可有效治疗兔VX2乳腺癌区域淋巴组织转移。     

活性碳吸附丝裂霉素局部给药治疗腋淋巴结阳性乳腺癌模型的疗效研究

目的:研究丝裂霉素-活性碳混悬液(MMC-CH)局部注射给药对腋淋巴结阳性的兔乳腺癌模型的治疗效果。方法:30只雌性新西兰兔随机分为三组,每组10只,VX2肿瘤组织块悬液注射法建立乳腺癌模型,腋淋巴结最大径达到5mm时开始治疗。A组:肿瘤周围皮下注射MMC-CH;B组:肿瘤周围皮下注射丝裂霉素水溶剂(MMC-Sol);C组:注射生理盐水。A、B组单次药物剂量0·2mg/kg,每48h重复给药1次,3次治疗后切除淋巴结。比较治疗前后淋巴结体积变化,病理切片观察转移灶癌组织坏死,dTUP末端标记技术(TUNEL)检测癌细胞凋亡指数(AI),组间差异比较采用ANOVA-Dunnett检验。结果:与MMC-Sol相比,局部注射MMC-CH对腋淋巴结癌转移灶表现出更为显著的疗效。治疗后A、B、C组淋巴结平均生长率分别为2·645、3·175和3·518,A组显著低于B、C组(P值分别为0·012和0·000)。A、B、C组平均AI值分别为15·94%、5·18%和4·60%,A组显著高于B组(P=0·000),B组又显著高于C组(P=0·020)。病理检查发现,A组淋巴结转移癌细胞大量坏死。结论:局部注射MMC-CH可有效治疗兔VX2乳腺癌区域淋巴组织转移。     

乳腺癌腋淋巴结隐匿性转移的预后

乳腺癌病理检查腋淋巴结转移状况是决定分期、病人预后和指导术后辅助治疗的一个最重要的指标［１］。寻找腋淋巴结阴性乳腺癌病人的预后指标以指导术后辅助治疗是乳腺癌研究领域的一大热点。本文研究常规病理检查诊断为腋淋巴结阴性乳腺癌（ＡＮＮ）病人其腋淋巴结隐匿性...     

腋淋巴结阳性乳腺癌结外侵犯的临床意义

目的 探讨乳腺癌患者淋巴结外侵犯(ECE)的临床意义.方法 回顾性分析1230例腋窝淋巴结阳性乳腺癌,观察ECE与临床病理指标之间关系及对患者预后的影响.结果 腋窝淋巴结阳性乳腺癌患者中,ECE阳性率为39.5%.绝经前和绝经后患者ECE的发生率分别为35.5%和47.5%(P＜0.001).ECE阳性组和阴性组的肿瘤直径分别为5.11±2.53 cm和3.90±1.80 cm(P＜0.001),肿瘤直径越大,ECE阳性比例越高(P＜0.001).ECE阳性患者和ECE阴性患者的阳性淋巴结数目分别为16.96±12.16和5.24±6.60(P＜0.001),随腋窝阳性淋巴结数目增多,ECE阳性率明显增加(P＜0.001).ECE的发生与ER、PR状态无显著相关(P=0.706).ECE足乳腺癌患者局部或区域复发的危险因素(P＜0.001),复发时间差异无统计学意义(P=0.559).ECE阳性组和ECE阴性组的远处转移时问分别为30.0个月和37.5个月(P=0.006).首发骨、皮肤和远隔淋巴结组及内脏转移组的ECE阳性率分别为60.4%和42.0%(P=0.001).ECE阳性患者的无转移生存时间、无局部或区域复发生存时间及总生存时间均小于ECE阴性患者.预后单因素和多因素分析显示,ECE是影响乳腺癌患者无转移生存时间、无局部或区域复发生存时间及总生存时间的独立危险因素.结论 乳腺癌患者ECE的发生与肿瘤直径和受累淋巴结数日呈正相关;ECE是乳腺癌局部或区域复发和远处转移的危险因素;ECE是影响乳腺癌患者无转移生存时间、无局部或区域复发生存时间及总生存时间的危险因素.     

腋淋巴结阴性乳腺癌的预后和辅助化疗

本文分析上海医科大学肿瘤医院外科１９８０年１月至１９９２年１２月，手术治疗单侧原发性乳腺癌４３９例，所有病例均经病理证实无区域淋巴结转移。４３９例中行改良根治术者４３例，根治术１０３例，扩大根治术２９３例，其中单纯手术者１７５例，术后行ＣＭＦ方案辅助化疗者２６４例，两组资料的临床特征相似（Ｐ〈０．０５），有可比性，随访至１９９４年１２月，随访率９７．９５％，资料输入计算机按寿命表法统计生存率，结果     

787例乳腺癌患者腋淋巴结转移的影响因素

目的 探讨乳腺癌腋淋巴结转移的影响因素.方法 回顾性分析2006年12月至2008年11月在山西省肿瘤医院诊治的乳腺癌患者.采用Logistic回归分析,检查乳腺癌腋淋巴结转移与患者年龄、肿瘤大小、肿瘤病理类型、雌激素受体(ER)、孕激素受体(PR)、人类表皮生长因子受体2(Her-2)等因素的关系.结果 1133例乳腺癌患者中,具有完整的腋淋巴结手术及其他临床病理资料者787例(69.5%).平均每例清扫淋巴结14.6枚,平均每例淋巴结转移3.5枚.肿瘤大小与淋巴结转移呈正相关.多变量Logistic回归分析显示,患者年龄、肿瘤大小、ER状态、肿瘤病理类型与乳腺癌腋淋巴结转移有显著的相关性(P<0.05).结论 肿瘤大小、患者年龄、ER状态及病理类型是乳腺癌腋窝淋巴结转移的影响因素.

Abstract：

Objective To explore the predictors of axillary nodal metastass in patients with breast cancer.Methods A retrospective study was performed using the clinicopathological data of breast cancer cases diagnosed and treated in our Hospital between Dec 2006 and Nov 2008.Logistic regression analysis was used to determine the predictors of axillary node positivity.Results The total number of patients was 1133.69.5% of them (787) had complete clinical and pathological data.The median age was 49 years old ( range 20-85 ).The average number of lymph nodes removed was 14.6 per person.The average number of involved nodes was 3.5 per person.Increasing tumor size was associated with increased risk of lymph node metastases.Assessed by multivariate analysis, the tumor size, age, ER status, and pathological type were significantly associated with node metastasis.Conclusions Axillary nodal metastases are significantly affected by the tumor size, ER status, age, and pathological type in breast cancer patients.     

Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2‐positive breast cancer

BACKGROUND:

The axillary pathologic complete response rate (pCR) and the effect of axillary pCR on disease‐free survival (DFS) was determined in patients with HER2‐positive breast cancer and biopsy‐proven axillary lymph node metastases who were receiving concurrent trastuzumab and neoadjuvant chemotherapy. The use of neoadjuvant chemotherapy is reported to result in pCR in the breast and axilla in up to 25% of patients. Patients achieving a pCR have improved DFS and overall survival. To the authors' knowledge, the rate of eradication of biopsy‐proven axillary lymph node metastases with trastuzumab‐containing neoadjuvant chemotherapy regimens has not been previously reported.

METHODS:

Records were reviewed of 109 consecutive patients with HER2‐positive breast cancer and axillary metastases confirmed by ultrasound‐guided fine‐needle aspiration biopsy who received trastuzumab‐containing neoadjuvant chemotherapy followed by breast surgery with complete axillary lymph node dissection. Survival was evaluated by the Kaplan‐Meier method. Clinicopathologic factors and DFS were compared between patients with and without axillary pCR.

RESULTS:

Eighty‐one patients (74%) achieved a pCR in the axilla. Axillary pCR was not associated with age, estrogen receptor status, grade, tumor size, initial N classification, or median number of lymph nodes removed. More patients with an axillary pCR also achieved a pCR in the breast (78% vs 25%; P < .001). At a median follow‐up of 29.1 months, DFS was significantly greater in the axillary pCR group (P = .02).

CONCLUSIONS:

Trastuzumab‐containing neoadjuvant chemotherapy appears to be effective in eradicating axillary lymph node metastases in the majority of patients treated. Patients who achieve an axillary pCR are reported to have improved DFS. The success of pCR with concurrent trastuzumab and chemotherapy in eradicating lymph node metastases has implications for surgical management of the axilla in these patients. Cancer 2010. © 2010 American Cancer Society.     

新辅助化疗对腋窝淋巴结数量影响随机对照临床研究

目的：探讨新辅助化疗（neoadjuvant chemotherapy,NAC）对乳腺癌患者腋窝淋巴结数量的影响。方法：2010—03—02—2012—06—30临沂市人民医院乳腺外科收治82例临床Ⅱ～Ⅲ期乳腺癌患者,随机数字表法分为化疗组40例和手术组42例,化疗组以蒽环类CEF或EC方案行3～4个周期NAC,手术组直接接受乳腺癌改良根治术,比较两组患者的腋窝淋巴结数量。结果：40例经NAC的乳腺癌患者中,目标病灶完全缓解（CR）6例,部分缓解（PR）19例,病情稳定（SD）15例,无患者出现疾病进展（PD）。腋窝淋巴结清除以后,化疗组平均检出淋巴结总数为16．7枚（8～28枚）,手术组为20．4枚（12～37枚）;平均阳性淋巴结数化疗组为2．1枚（0～13枚）,手术组为6．5枚（0～20枚）,两组间差异均有统计学意义,P值均〈0．001。结论：乳腺癌患者接受NAC以后,进行腋窝淋巴结清除时,不仅阳性淋巴结减少,得到的淋巴结总数也减少。     

乳腺癌新辅助化疗后前哨淋巴结活检意义的前瞻性研究

目的:探讨乳腺癌患者新辅助化疗(NAC)后腋窝前哨淋巴结活检的可行性.方法:采用99Tc硫胶体联合亚甲蓝示踪法对60例NAC后达到临床腋淋巴结阴性的乳腺癌患者和60例临床腋淋巴结阴性的早期乳腺癌患者进行腋窝前哨淋巴结活检术(SLNB),评估SLNB的检出率和准确性,比较两组患者SLNB的检出率和假阴性率,并分析NAC后SLNB检出率和假阴性率与患者及肿瘤特点的关系.结果:60例NAC后患者的前哨淋巴结(SLN)检出率为90%,SLNB的敏感度为90%,特异度为93.33%,准确性为91.67%,假阴性率为10%.其检出率和假阴性率与早期乳腺癌组比较,差异均无统计学意义(P=0.743,P=1.000).NAC组化疗前临床分期T3或N2以上者,腋淋巴结的检出率均显著下降,差异有统计学意义(P=0.030,P=0.000),分期N2以上者假阴性率显著增高,差异有统计学意义,P=0.001.结论:对NAC后达到临床淋巴结阴性的乳腺癌患者,腋窝SLN的检出率和假阴性率与早期乳腺癌SLNB差异无统计学意义,化疗前的TN分期是SLNB检出率和假阴性影响因素.     

乳腺癌患者新辅助化疗前后淋巴管密度检测

背景与目的:淋巴管生成在肿瘤经淋巴途径转移中所起的作用已成为近几年里新的研究热点,但目前的研究结果仍存在很多争议。本研究拟检测乳腺癌患者新辅助化疗前后的淋巴管密度(lymphatic vessel density,LVD)并与乳腺良性病变进行比较,以进一步明确淋巴管生成的意义及其在化疗过程中的变化。方法:45例原发性乳腺癌患者给予3个周期新辅助化疗并手术,免疫组化法标记肿瘤及26例纤维腺瘤标本中特异性淋巴管内皮标志物Podop lan in并计数LVD。结果:乳腺癌瘤周、瘤内的淋巴管阳性率分别为70.9%、19.8%。化疗前瘤周平均LVD为9.6,纤维腺瘤瘤周平均LVD为5.4,两者间差异有显著性(P=0.012)。化疗后瘤周平均LVD为3.3,与化疗前相比显著降低(P<0.001),化疗前、后瘤内平均LVD分别为1.9、0.9(P=0.055)。淋巴结转移阳性和阴性组的平均瘤周LVD分别为11.8、7.0(P=0.048)。化疗后客观缓解组化疗前后平均瘤周LVD值分别为9.8、2.0(P<0.001)。结论:与良性病变相比,乳腺癌瘤周LVD显著增高;有瘤内淋巴管存在;瘤周LVD与HER-2、腋淋巴结转移状态相关;化疗后瘤周LVD明显降低,而瘤内LVD无显著变化;化疗后瘤周LVD的降低程度与化疗疗效相关。     

长春瑞滨为主的联合方案治疗晚期乳腺癌临床疗效观察

目的探讨长春瑞滨为主的联合方案治疗蒽环类和（或）紫杉类耐药晚期乳腺癌的疗效与安全性。方法82例蒽环类和（或）紫杉类耐药的转移乳腺癌患者分为两组：（1）长春瑞滨联合顺铂组（NP组）61例：长春瑞滨25 mg/m2,第1天和第8天,静脉滴注;顺铂75~80 mg/m2,静脉滴注,分割为2-5天。（2）长春瑞滨联合氟尿嘧啶类组（NF组）21例：诺维本用法同NP组,卡培他滨800~1 000 mg/m2,分早晚两次餐后30分钟口服,第1-14天,或替加氟600 mg/m2,第2-6天。3周为1周期,每2周期治疗结束2周后评价疗效。结果82例均可评价近期疗效和毒副作用,NP方案组总有效率为60.7%（37/61）,CR 3.3%（2/61）,PR 57.4%（35/61）,SD 36.2%（22/61）,PD 3.3%（2/61）。既往放疗者疗效好于未放疗者（P=0.025）,转移部位为单个者疗效好于多个者（P=0.017）;NF组总有效率为38.1%,CR 4.8%（1/21）,PR 33.3%（7/21）,SD 52.4%（11/21）,PD 9.5%（2/21）,蒽环类耐药者疗效好于蒽环类和紫杉类耐药者（P=0.020）。两组主要不良反应为骨髓抑制和胃肠道反应。结论长春瑞滨联合方案是治疗蒽环类和（或）紫杉类耐药转移性乳腺癌的有效解救方案。     

Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.

PURPOSE: Pathologic complete remission (pCR) of primary breast tumors after primary chemotherapy (PCT) is associated with higher relapse-free survival (RFS) and overall survival (OS) rates. The purpose of this study was to determine long-term outcome in patients achieving pCR of cytologically proven axillary lymph node (ALN) metastases. METHODS: Patients with cytologically documented ALN metastases were treated in five prospective PCT trials. After surgery, patients were subdivided into those with and without residual ALN carcinoma. Survival was calculated by the Kaplan-Meier method. RESULTS: Of 925 patients treated, 403 patients had cytologically confirmed ALN metastases. Eighty-nine patients (22%) achieved ALN pCR after PCT. Compared with the group without ALN pCR, 5-year OS and RFS were improved in patients achieving ALN pCR (93% [95% CI, 87.5 to 98.5] and 87% [95% CI, 79.7 to 94.3] v 72% [95% CI, 66.5 to 77.5] and 60% [95% CI, 54.1 to 65.9], respectively; P < .0001). Residual primary tumor did not affect outcome of those with ALN pCR. Combination anthracycline/taxane-based PCT resulted in significantly more ALN pCRs, although outcome after ALN pCR was not improved by taxanes. We constructed a nomogram demonstrating that patients who do not benefit from neoadjuvant anthracyclines are unlikely to benefit from subsequent taxanes. CONCLUSION: ALN pCR is associated with an excellent prognosis, even with a residual primary tumor, pointing to biologic differences between primary and metastatic cells. ALN pCR represents an early surrogate marker of long-term outcome. Response to initial PCT has important potential as a guide to subsequent therapy.     

淋巴结转移10枚及以上的原发乳腺癌回顾性研究

目的：回顾性分析10枚及以上腋窝淋巴结转移原发乳腺癌各临床病理因素、辅助治疗方法与预后的关系。方法：对病理确诊且腋窝淋巴结转移10枚及以上原发乳腺癌患者186例，采用X^2检验和COX模型，分析诊断年龄、肿物大小、临床分期、术式、术前化疗状态、术后化疗状态、术后放疗状态、术后内分泌治疗状态、受体状态与预后的关系。结果：临床病理因素和辅助治疗方法与3、5年复发率和3、5年转移率差异均无统计学意义，P〉0．05。肿物大小与10年生存率、5年和10年无瘤生存率差异均有统计学意义，P〈0．05。临床分期10年无瘤生存率差异有统计学意义（P=0．030），而与5、10年生存率和5年无瘤生存率差异均无统计学意义，P〉0．05。术后辅助化疗、术后辅助放疗和术后辅助内分泌治疗5、10年无瘤生存率及5、10年生存率差异均有统计学意义，P〈0．05。诊断年龄、术式、激素受体状态和术前化疗状态与5年无瘤生存率、10年无瘤生存率及5、10年生存率差异均无统计学意义，P〉0．05。COX模型分析结果仅术后化疗状态是与预后相关的辅助治疗方法。结论：对于10枚及以上淋巴结转移原发乳腺癌其预后与临床病理因素和辅助治疗的选择相关。     

Prognostic significance of occult axillary lymph node metastases after chemotherapy‐induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer

BACKGROUND:

Primary systemic chemotherapy has been a standard of care for the management of locally advanced breast cancer (LABC) patients and has increasingly been used for patients with large operable breast cancer. Pathologic complete response (pCR) of axillary lymph node metastases predicted an excellent probability of long‐term disease‐free and overall survival. Although the clinical significance of occult lymph node metastases in patients with breast cancer was extensively studied, their prognostic value in patients with LABC after primary chemotherapy was not known. This study evaluated the detection rate and clinical significance of occult lymph node metastases in lymph nodes that contained metastatic carcinoma at the time of initial diagnosis and converted to negative based on routine pathologic examination after primary systemic chemotherapy.

METHODS:

Fifty‐one patients with LABC and cytologically involved axillary lymph nodes that converted to negative after preoperative chemotherapy were identified from 2 prospective clinical trials. All lymph node sections were reviewed, 1 deeper level hematoxylin and eosin‐stained section of each lymph node was obtained and immunohistochemical staining for cytokeratin (CK) was performed. A total of 762 lymph nodes were evaluated for occult metastases. Kaplan‐Meier survival curves were used for calculating disease‐free and overall survival times.

RESULTS:

Occult axillary lymph node metastases were identified in 8 of 51 (16%) patients. In 6 patients, occult metastases were found in only 1 lymph node. In 7 patients, only isolated CK‐positive cells were identified. In all cases, occult carcinoma cells were embedded within areas of fibrosis, foreign body giant cell reaction, and extensive histiocytosis. Patients with occult lymph node metastases tended to have a higher frequency of residual primary breast tumors than those without occult metastases (4 of 8 vs 7 of 43, respectively). There was no statistically significant difference in disease‐free or overall survival times between patients with and without occult metastases after a median follow‐up 63 months.

CONCLUSIONS:

Persistent occult axillary lymph node metastases were not uncommon in patients with axillary lymph node‐positive LABC who experienced a pCR in involved lymph nodes after preoperative chemotherapy. However, such occult metastases did not adversely affect the good prognosis associated with axillary lymph node pCR. Therefore, routine lymph node CK evaluation was not recommended after primary chemotherapy. Cancer 2009. © 2009 American Cancer Society.     

国产多西紫杉醇联合顺铂治疗晚期乳腺癌的临床研究

为评价以国产多西紫杉醇（商品名多帕菲）联合顺铂治疗晚期乳腺癌的近期疗效和不良反应。多帕菲60mg／m^2，静脉滴入，d1；顺铂80mg／m^2，静脉滴入，d1～d3。21d为1个周期，一般至少用2个周期后评价疗效。全组35例，CR4例，PR16例，SD7例，PD8例，总有效率（CR＋PR）57．1％。初治有效率62．5％，复治有效率55、5％。主要不良反应为骨髓抑制，其次为胃肠道反应。以多帕菲联合顺铂的化疗方案对晚期乳腺癌呈现较高疗效，同时多帕菲具有使用方便、安全，优异的性价比，不失为一种好的解救化疗方案。